A5040330750- Cystic Fibrosis Research Advances
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Neonatal Respiratory Health Research
- Pediatric health and respiratory diseases
- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Advanced Chemical Sensor Technologies
- IL-33, ST2, and ILC Pathways
- Respiratory viral infections research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Tracheal and airway disorders
- Pneumonia and Respiratory Infections
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Allergic Rhinitis and Sensitization
- Atrial Fibrillation Management and Outcomes
- Tuberculosis Research and Epidemiology
- Connexins and lens biology
- Mycobacterium research and diagnosis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Sodium Intake and Health
- Mast cells and histamine
- Delphi Technique in Research
Amsterdam University Medical Centers
2019-2023
University of Amsterdam
2014-2023
Karolinska University Hospital
2020
Respiratory Clinical Trials
2020
The University of Melbourne
2020
RELX Group (United States)
2020
Amsterdam UMC Location University of Amsterdam
2011-2018
Advanced Cell Diagnostics (United States)
2017
Canadian Respiratory Research Network
2016
Radboud University Nijmegen
2006-2007
Rectal organoids from subjects with cystic fibrosis can be used to assess responses drugs that modulate CFTR.
In vitro drug tests using patient-derived stem cell cultures offer opportunities to individually select efficacious treatments. Here, we provide a study that demonstrates in responses rectal organoids from individual patients with cystic fibrosis (CF) correlate changes two vivo therapeutic endpoints. We measured efficaciousness functional assay rectum-derived based on forskolin-induced swelling and studied the correlation effects. The organoid correlated both change pulmonary response sweat...
Abstract Background Activated eosinophils cause major pathology in stable and exacerbating asthma; however, they can also display protective properties like an extracellular antiviral activity. Initial murine studies led us to further explore a potential intracellular activity by eosinophils. Methods To follow eosinophil‐virus interaction, respiratory syncytial virus (RSV) influenza were labeled with fluorescent lipophilic dye (DiD). Interactions visualized confocal microscopy, electron flow...
Asthma is a chronic inflammatory airway disease, associated with episodes of exacerbations. Therapy inhaled corticosteroids (ICS) targets inflammation, which aims to maintain and restore asthma control. Clinical features are only modestly airways inflammation. Therefore, we hypothesized that exhaled volatile metabolites identify longitudinal changes between clinically stable loss control.To determine whether organic compounds (VOCs) as measured by gas-chromatography/mass-spectrometry (GC/MS)...
Increasing evidence suggests that patients with asthma have activated coagulation within the airways. Whether this leads to an increase in venous thromboembolic events is unknown. We therefore assessed incidence of mild-to-moderate and severe as compared age- sex-matched reference population. 648 (283 365 asthma) visiting three Dutch outpatient clinics were studied. All completed a questionnaire about diagnosis deep vein thrombosis pulmonary embolism past, their risk factors, history...
Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma, therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 efficiently attenuates eosinophils, proved clinically effective severe asthma but not mild asthma.To study effect mepolizumab virus-induced immune responses asthma.Patients with steroid-naive randomized for numbers, received 750 mg intravenously placebo-controlled...
Abstract In the Netherlands, 1.4% of tuberculosis (TB) cases are caused by Mycobacterium bovis. After we admitted 3 patients with M. bovis infections to our reference hospital, conducted a retrospective analysis all disease in Netherlands during 1993–2007. We analyzed data from 231 for clinical, demographic, treatment, and outcome characteristics risk factors. Most were native Dutch (n = 138; 59.7%) or Moroccan 54; 23.4%). Disease was mainly extrapulmonary 136; 58.9%). Although 95 had...
Rationale Targeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores chloride channel function and improves epithelial fluid transport in the airways. Consequently, changes may occur microbiome, which is adapted to CF lungs. Objectives To investigate effects of on respiratory microbial composition metabolic activity by repeatedly sampling lower tract. Methods This was a single-centre longitudinal observational cohort study adult patients homozygous Phe508del mutation....
<h2>Abstract</h2> Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in people with cystic fibrosis (CF) heterozygous for <i>F508del</i> a minimal function mutation (<i>F</i>/MF) or homozygous (<i>F</i>/<i>F</i>) two pivotal Phase 3 trials, significantly improving percentage predicted forced expiratory volume 1 second, Cystic Fibrosis Questionnaire–Revised, Respiratory Domain (CFQ-R RD) scores, sweat chloride concentration. Here, we analyzed the 11...
Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane conductance regulator modulator, which has shown efficacy in CF patients (≥6 years) with ≥1 Phe508del mutation and minimal function mutation. In October 2019, ETI became available on compassionate use basis for Dutch severe lung disease. Our objective was to investigate safety of this patient group real-life setting. A multicenter longitudinal observational study conducted examine changes FEV1 , BMI, adverse...
We hypothesized that people with cystic fibrosis (CF) who express CFTR (cystic transmembrane conductance regulator) gene mutations associated residual function may benefit from G-protein coupled receptor (GPCR)-targeting drugs can activate and enhance function. used intestinal organoids to screen a GPCR-modulating compound library identified β 2 -adrenergic agonists as the most potent inducers of -Agonist-induced organoid swelling correlated genotype, could be induced in homozygous...
The novel cystic fibrosis transmembrane conductance regulator (CFTR) modulators, ivacaftor, lumacaftor, and tezacaftor, are the first drugs directly targeting underlying pathophysiological mechanism in (CF); however, independent studies describing their pharmacokinetics lacking. aim of this study was to develop a quantification method for ivacaftor its 2 main metabolites, lumacaftor plasma sputum using liquid chromatography with tandem mass spectrometry.
Asthma patients show evidence of a procoagulant state in their airways, accompanied by an impaired function the anticoagulant protein C system. We aimed to study effect recombinant human activated (rhAPC) allergic asthma patients. conducted randomised, double-blind, placebo-controlled, proof-of-concept house dust mite (HDM) Patients were randomised receive intravenous rhAPC (24 µg·kg −1 ·h ; n=12) or placebo (n=12) for 11 h. 4 h after start infusion, first bronchoscopy was performed...
Ivacaftor has been shown to restore the functionality of S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology micro-environment, resulting a change microbiota these organs. The aim present study was analyze effects ivacaftor on microbial community composition subjects with CF carrying one mutation, using 16S rRNA gene-based sequencing approach. In 16 CF, repetitive samples from airways were collected just before, 2 months after, and,...